Objective: To test for association of the ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) K121Q polymorphism with body mass index (BMI) and diabetes in a large sample of Caucasians and African-Americans by selectively genotyping individuals at the extremes of the phenotypic distribution. Subjects: Subsets comprising the extremes of the BMI distribution (10th-20th and above the 90th BMI percentile for Caucasians and between the 10th-30th and above the 80th percentile for African-Americans) from a group of 10 260 Caucasian and 2268 African-American adults participating in New York Cancer Project were studied. Methods: Subjects were genotyped for the ENPP1 K121Q polymorphism by pyrosequencing and tested for association with BMI and diabetes by regression analysis. Results: Regression analysis with BMI as the dependent variable demonstrated a significant association (P ¼ 0.02) of genotype at K121Q with BMI, with no significant race-by-genotype interaction (P ¼ 0.30). Compared with Q/Q or Q/K individuals, the K/K individuals had a BMI approximately 1.3 kg/m 2 higher, without effects of age, gender or race. By logistic regression analysis, the K121Q alleles had no significant effect on diabetes status (P ¼ 0.37) in obese subjects. Conclusion: In both Caucasians and African-Americans, the K121 polymorphism in ENPP1 was associated with increased BMI, but not with diabetes.
Introduction
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1 (membrane glycoprotein PC-1)) (OMIM #173335, NCBI: NM_006208) was originally described as a plasma cell alloantigen and named plasma cell membrane glycoprotein (PC-1). 1, 2 In addition to plasma cells, ENPP1 is widely expressed in the muscle, liver, renal tubules, salivary duct epithelium, epididymis, adipose tissue, chondrocytes, pancreas, and capillary endothelium in the brain. 2 ENPP1 is a class II transmembrane glycoprotein with a short aminoterminal cytoplasmic tail, a single transmembrane domain, and a large extracellular carboxy-terminal domain 1 that generates inorganic pyrophosphate (PPi) from nucleoside triphosphates (NTPs) and other PPi sources. The K121Q polymorphism (rs1044498) is located in the extracellular somatomedin-B domain, adjacent to the transmembrane domain. Maddux et al. 3 reported that overexpression of ENPP1 in human MCF-7 breast cancer cells inhibited tyrosine kinase activity of the insulin receptor (IR). They also demonstrated a physical interaction between IR and ENPP1 by immunoprecipitation with an IR-specific monoclonal antibody. Constanzo et al. 4 showed that the human Q121 allele has more potent inhibitory effects on IR autophosphorylation than the K121 allele in vitro. Q121 carriers have been reported to have higher plasma glucose and insulin during oral glucose tolerance testing (OGTT), and relative insulin resistance as measured by euglycemic clamp in some studies [5] [6] [7] [8] [9] but not others. 10, 11 Meyre et al.
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reported that obese French children have a higher frequency of the Q121 allele than nonobese controls. Jenkinson et al. 13 demonstrated that the Q121 allele was the only nonsynonymous coding single-nucleotide polymorphism (SNP) in a comprehensive analysis of all SNPs within ENPP1 associated with 'diabesity' phenotypes in Mexican-Americans. The Q121 allele has also been associated with diabetic nephropathy in type 1 diabetic patients 14, 15 and early myocardial infarction. 16 Rutsch et al. 17, 18 reported that, in humans, 'idiopathic' infantile arterial calcification (IIAC) characterized by periarticular and aortic calcifications is associated with homozygous loss of function mutations in ENPP1.
To test the association of ENPP1 K121Q alleles with obesity and diabetes in additional ethnicities and test the utility of selectively genotyping subjects selected from the extremes of the body mass index (BMI) distribution of a large study sample, we tested the association of ENPP1 K121Q alleles with BMI and diabetes in a subset of 670 Caucasians and 321 African Americans selected from a larger group of 17 All subjects with a history of cancer were eliminated from the study groups to eliminate the possible effect of cancer and its treatment on body weight. Caucasian and African-American subjects were separately sorted by ascending BMI. Subjects below the 10th percentile for BMI were not included to avoid the confounding effects of medical conditions that themselves might cause weight loss. Caucasians between the 10th-20th percentile and above the 90th percentile and African-Americans between the 10th-30th and above the 80th percentile were selected for genotyping (Table 1) .
Genotyping
Genomic DNA was extracted from whole blood according to standard procedures (http://www.biorep.org/protocols/ biorepositoryprotocol.asp) and stored at 41C. 
Statistical analysis
Statistical analysis was conducted with Statistical Analysis System (SAS) ver. 9.0 (SAS Institute Inc., Cary, NC, USA). Hardy-Weinberg equilibrium at ENPP1 codon 121 was tested by a w 2 goodness of fit test. Data were adjusted for the covariates gender, age, age 2 , race, and two-way interactions of the covariates using regression analysis. A twodegree-of-freedom (df) test was performed by jointly testing the additive and dominant effects of the ENPP1 K121Q genotype on BMI after adjusting for the covariate effects. The additional effects of interactions between race-andadditive-effect and race-and-dominant-effect were also tested. As a form of sensitivity analysis, a new variable, BMI R , was created by ranking BMI. The regression analysis was then also performed on BMI R , offering a more robust semiparametric test. 20 Lean subjects were not included in the analysis for diabetes because the number of subjects with diabetes in the lean groups was small (Caucasian n ¼ 3, African-American n ¼ 4) and less likely to represent type 2 diabetes. In all, 11.2% of Caucasians above the 90th percentile for BMI (age 53.8710.4 years old (mean7SD), female n ¼ 22, male n ¼ 15) and 14.4% of African-Americans above the 80th percentile for BMI (age 50.079.5 years old, female n ¼ 18, male n ¼ 6) had diabetes. We analyzed diabetes as a binary outcome by logistic regression analysis. Diabetes was treated as a dependent variable and race, age, gender, and allele dose (additive effect of genotype coded as Q ¼ 1, K ¼ 0) as independent variables. We also performed logistic regression of the binary trait diabetes using race, gender, age, age 2 , and interaction terms as covariates to see the combined effect of additive and dominance effects on diabetes.
Results
Genotype frequencies are given in Table 3 ). We observed a significant association of age and race with diabetes status (P ¼ 0.04 and o0.001), but no effect of the ENPP1 K121Q polymorphism on diabetes status by logistic regression analysis (P ¼ 0.17). The 2-df test had P-value ¼ 0.603 and hence the combined effect of additive and dominance effects on diabetes, after adjusting for covariates, was not statistically significant. 
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Discussion
The K121 allele of ENPP1 was associated with increased BMI in both Caucasians and African-Americans. K/K individuals had higher BMI than either Q/K or Q/Q individuals. Although the increase in BMI in K/K homozygous individuals vs K/Q þ Q/Q subjects is modest (1.3 kg/m 2 ), the high frequency of the K121 susceptibility allele, especially in Caucasians, could be one of the common genetic variants with small effects that additively or synergistically determine adiposity in a large portion of the population. By employing a strategy of sampling the extremes of the BMI distribution of a large study sample, we were able to detect this relatively modest effect on BMI that might not have been apparent in smaller studies. This emphasizes the need to have large sample sizes of thousands of subjects in genetic studies of complex traits. Our data do not demonstrate an association of the K121 allele with diabetes mellitus. However, we used a gross measure of diabetes affection status without precise endophenotypic measures of insulin sensitivity or beta cell function, and the number of diabetic subjects in our study was small, in part because the mean age of our subjects was under 50. Our sample size may not be adequate to fully address the question of association with diabetes or insulin resistance.
The frequency of the K121 allele in Caucasians in our study is similar to that found in previous studies, [5] [6] [7] [8] 10, 11 and has been reported to be much higher in Caucasians (79.9%) than African-Americans (25.9%) or Dominicans (45.8%).
9
Although the K121 allele frequency is higher in Caucasians than African-Americans in our study sample, the average BMI at each percentile was higher in African-Americans than in Caucasians. Clearly, there must be other genetic and/or environmental factors beyond ENPP1 that account for the racial differences in susceptibility to increased adiposity.
Others have reported linkage of 6q23-25, the interval where ENPP1 maps, with BMI and/or insulin sensitivity in Caucasians in the Framingham Study, 21 non-diabetic Mexican-Americans, 22 and French-Caucasians. 23 These linkage peaks include ENPP1, and the K121 allele or other ENPP1 polymorphisms could account for part or all of these linkages. Previous studies have demonstrated associations of the Q121 allele with increased adiposity in Caucasian children and Mexican-Americans and increased fasting plasma glucose and insulin resistance in adult Caucasians, Mexican Americans, Spaniards, and Dominicans. [5] [6] [7] [8] [9] 12, 13 In contrast, we found a higher K121 allele frequency in our adult obese Caucasian and African-American subjects, and do not have sufficient endophenotypic data to address the possible role of K121Q alleles on insulin homeostasis in our sample. Our association of the K121 rather than the Q121 allele with increased BMI could reflect differences in the effects of the two alleles on weight gain at different ages (Caucasians), or in different racial groups (AfricanAmericans). Alternatively, the K121 allele may be in linkage disequilibrium with other ENPP1 polymorphisms (or other genes) in our study sample that is genetically different (African-Americans) and perhaps more heterogeneous (Caucasians) than the samples studied previously. Several studies have demonstrated an association of the Q121 allele with insulin resistance in adults, [5] [6] [7] [8] [9] but these studies have failed to demonstrate an association of this allele with obesity. [5] [6] [7] [8] [9] [10] [11] However, the range of BMIs in these studies was between 24 and 28 kg/m 2 , with sample sizes that were much smaller than our study, and were not powered to detect small BMI effects of the magnitude we report. Due to the high frequency of the K/K genotype in Caucasians, the effect of the 1.3 kg/m 2 increase in BMI we detected could significantly increase the obesity-related risk of many co-morbid conditions such as coronary artery disease, diabetes, and cancer. 24 Further genetic characterization of polymorphisms in ENPP1 in additional samples, with precise, prospective data on energy and glucose homeostasis, especially from those samples demonstrating linkage to 6q22-23, will help to clarify the potential contributions of this gene to both adiposity and diabetes.
